Aims
The trans-and gender-diverse (TGD) population is growing and ageing. Bone health is affected by sex hormones which are integral to the medical transition undertaken by many TGD individuals for gender affirmation. This systematic review aims to determine the impact of gender affirming hormone therapy (GAHT) on bone outcomes in TGD adults and older adults.
Methods
A systematic search of EMBASE, PsychINFO and Medline was conducted up to May 2025 to identify studies evaluating the bone health of adults on GAHT with, or without gender-affirming surgery. Abstracts and full texts were screened by three reviewers and full texts extracted by one reviewer with sample cross-checks. The Newcastle-Ottawa Scale tool was used to assess risk of bias and narrative synthesis was performed.
Results
A total of 5525 articles were screened and 36 met inclusion criteria for extraction. Only four studies stratified for age. No studies specifically examined the impact of GAHT on the bone health of adults aged >65 years. Pre-GAHT commencement, trans women had poorer bone health compared with members of their sex recorded at birth, in contrast to trans men. Long-term, GAHT may have a neutral or possibly positive effects on bone health in both transwomen and transmen but findings were inconsistent in studies of persons who underwent gender affirming surgery that included gonadectomy, which likely confounded long-term follow-up studies.
Conclusions
High quality research to guide bone health management of older TGD people is limited and required to ensure person-centred care of this priority population.